Back to Ophthalmology



Ophthalmology Biosimilars Market Research

What are Biosimilars?

A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved product in terms of safety, purity, and potency (safety and effectiveness). A manufacturer developing a proposed biosimilar must demonstrate that its product is highly similar to the reference product by extensively analyzing the structure and function of both the reference product and the proposed biosimilar. In order to qualify as a biosimilar, the agent must also have the same route of administration and dose and be used for the same condition/s as the reference drug. Biosimilars may offer more affordable treatment options to patients than the existing FDA-approved products on which they are based.

Spherix Global Insights – Ophthalmology Biosimilars Market

Spherix’s Ophthalmology team covers the Ophthalmology Biosimilars Today and Tomorrow (US) in our Launch Dynamix, and Special Topix services. Spherix’s has the following studies publishing this year covering Biosimilars:

  • Launch Dynamix™: Byooviz (Biogen / Samsung) and Cimerli (Coherus BioSciences) Ranibizumab Biosimilar (US)
  • Special Topix™: Ophthalmology Biosimilars Today and Tomorrow (US)

Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch .

Spherix’s Special Topix™ service is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

Follow Spherix Ophthalmology on Social Media

Follow us for ophthalmology industry news, insights & analysis:


For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:

Lynn Price
Franchise Leader, Biosimilar
Email: [email protected]


Get more information on Our Ophthalmology Biosimilars Coverage